<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01397279</url>
  </required_header>
  <id_info>
    <org_study_id>CLAVA</org_study_id>
    <nct_id>NCT01397279</nct_id>
  </id_info>
  <brief_title>Assessment of Liver Glucose Metabolism in Diabetic Subjects</brief_title>
  <acronym>CLAVA</acronym>
  <official_title>Assessment of Liver Glucose Metabolism in Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is associated with hepatic insulin resistance. One consequence of insulin&#xD;
      resistance of the liver is an altered hepatic glucose metabolism. This study investigates&#xD;
      whether the whole body (M-value) and hepatic insulin sensitivity obtained by hyperinsulinemic&#xD;
      euglycemic clamp is influenced by a preceding intravenous glucose tolerance test (Botnia&#xD;
      Clamp) in subjects with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hyperinsulinemic euglycemic clamp represents the gold standard for measuring peripheral&#xD;
      insulin sensitivity. The insulin sensitivity is described by the M-value,which is calculated&#xD;
      from glucose infusion rates during the last 30min of the clamp.&#xD;
&#xD;
      Glucose is metabolised in the periphery: 50% by neural tissues, 20% by splanchnic bed and&#xD;
      liver, 15% by skeletal muscle, 5% by adipose tissue and 10% by blood cells and other tissues.&#xD;
      Under hyperinsulinemic conditions there is a strong shift in glucose utilization: 85%&#xD;
      skeletal muscle and 15% by neural tissues, splanchnic bed and liver, adipose tissue, blood&#xD;
      cells and other tissues. The contribution of skeletal muscle varies with different insulin&#xD;
      sensitivity.&#xD;
&#xD;
      We now want to investigate whether there is a difference in tissue-specific insulin&#xD;
      sensitivity measured from a Botnia clamp (intravenous glucose tolerance test (ivGTT) and&#xD;
      following clamp) and a single hyperinsulinemic euglycemic clamp? After a 60min ivGTT blood&#xD;
      glucose levels in type 2 diabetic subjects are still elevated compared to baseline. High&#xD;
      blood glucose levels can influence several parameters and may also affect insulin&#xD;
      sensitivity. Until now, it is not proven, that the clamp preceding ivGTT does not have a&#xD;
      significant influence on the M-value.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>M Value in hyperinsulinemic euglycemic clamp</measure>
    <time_frame>3h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin-suppressed endogenous glucose production (liver insulin sensitivity)</measure>
    <time_frame>3h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Newly Diagnosed Type 2 Diabetes (During the Last 12 Months)</condition>
  <arm_group>
    <arm_group_label>Botnia clamp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hyperinsulinemic euglycemic clamp following intravenous glucose tolerance test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hyperinsulinemic euglycemic clamp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hyperinsulinemic euglycemic clamp without previous intravenous glucose tolerance test</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intravenous glucose tolerance test</intervention_name>
    <description>Administration of a 30% weight-adapted glucose bolus intravenously.</description>
    <arm_group_label>Botnia clamp</arm_group_label>
    <other_name>ivGTT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hyperinsulinemic euglycemic clamp</intervention_name>
    <description>Intravenous administration of 20% glucose and insulin over 3 hours</description>
    <arm_group_label>Botnia clamp</arm_group_label>
    <arm_group_label>hyperinsulinemic euglycemic clamp</arm_group_label>
    <other_name>HEC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  newly diagnosed type 2 diabetes (during the last 12 months)or non-diabetic subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe chronic diseases&#xD;
&#xD;
          -  hepatitis B, C oder HIV infection&#xD;
&#xD;
          -  malignancies&#xD;
&#xD;
          -  immune suppressive therapy&#xD;
&#xD;
          -  psychiatric illnesses&#xD;
&#xD;
          -  drug or alcohol abuse&#xD;
&#xD;
          -  anemia&#xD;
&#xD;
          -  renal dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, Prof., MD</last_name>
    <role>Study Director</role>
    <affiliation>Director German Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Roden, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director German Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2011</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>hyperinsulinemic euglycemic clamp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

